Academic Journal
Epigenetic modulation in tuberculosis - mycobacterial defense mechanism to host immune responses.
| Τίτλος: | Epigenetic modulation in tuberculosis - mycobacterial defense mechanism to host immune responses. |
|---|---|
| Συγγραφείς: | Sundaram K; Department of Herbal Pharmacology and Environmental Sustainability, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Kanchipuram, Tamil Nadu, India., Rathinam S; Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Kanchipuram, Tamil Nadu, India., Bethunaickan R; Department of Immunology, Indian Council of Medical Research (ICMR)- National Institute for Research in Tuberculosis, Chennai, Tamilnadu, India.; Faculty of Medical Research, Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India., Ranganathan UD; Department of Immunology, Indian Council of Medical Research (ICMR)- National Institute for Research in Tuberculosis, Chennai, Tamilnadu, India.; Faculty of Medical Research, Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India., Dhanapal M; Department of Immunology, Indian Council of Medical Research (ICMR)- National Institute for Research in Tuberculosis, Chennai, Tamilnadu, India., Selvaraj H; Division of Medical Research, SRM Medical College Hospital and Research Centre, Chennai, Tamil Nadu, India., Prabhu V; Division of Medical Research, SRM Medical College Hospital and Research Centre, Chennai, Tamil Nadu, India. |
| Πηγή: | Frontiers in immunology [Front Immunol] 2026 Sep 01; Vol. 17, pp. 1943755. Date of Electronic Publication: 2026 Sep 01 (Print Publication: 2026). |
| Τύπος έκδοσης: | Journal Article; Review |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: [Lausanne : Frontiers Research Foundation] |
| Ιατρικοί όροι (MeSH): | Epigenesis, Genetic*/immunology , Mycobacterium tuberculosis*/immunology , Mycobacterium tuberculosis*/genetics , Tuberculosis*/immunology , Tuberculosis*/genetics , Tuberculosis*/microbiology , Tuberculosis*/metabolism , Host-Pathogen Interactions*/immunology , Host-Pathogen Interactions*/genetics, Histones/metabolism ; Humans ; Animals ; DNA Methylation |
| Περίληψη: | Epigenetic regulators alter chromatin to control transcription in response to pathogens. Histone acetylation influences DNA accessibility and gene expression, impacting latent and active tuberculosis (TB). Mycobacterium tuberculosis (MTB) requires specific components to harm the host immune system. The review aims to analyze MTB epigenetic processes and the impact of host immune system genes. This review analyzed histone deacetylases, DNA methyltransferases, epigenetic linkages to non-coding RNAs, and enhanced epigenetic detection. Also, it described mycobacteria's evasion of the host immune system through lipid metabolism, autophagy, oxidative stress, and epigenetic efflux pump inhibitors. The MTB DNA methyltransferase (DNMT) Rv2966c (I6XFS7) modifies histones H3 and H4, impacting host transcription. The MTB acetyltransferase EIS (Rv2416c, P9WFK7) enhances human IL-10 synthesis and acetylates the H3 gene promoter. MTB infection activates an epigenetic repressor complex with HDAC1 and ZBTB25, which restricts IL-12B production in macrophages. MTB inhibits HDAC1 and ZBTB25, enhances autophagic clearance, reduces bacterial viability, and increases IL-12B. ADP-ribosyl polymerase Rv1899c interacts with HDAC1 and may inhibit immune activation. Rv1899c interacts with HDAC1 and ZBTB25 to silence inflammatory promoters and maintain immune suppression without effector release. NLRP3 activation is influenced by DNA methylation. DNMT inhibitor DAC increased transcriptional activity in vitro, while DNA methylase Sss I decreased NLRP3 promoter activity. In small RNAs, links to epigenetics, the miR-15/16 family's miR-15a-5p, regulate apoptosis, the cell cycle, and inflammatory cytokines. MiR-15a-5p affects inflammation by targeting genes in the BCL2, IKKα, and NF-κB pathways. Thus, epigenetic studies on MTB are vital to identify host immune evasion and host-directed therapy. (Copyright © 2026 Sundaram, Rathinam, Bethunaickan, Ranganathan, Dhanapal, Selvaraj and Prabhu.) |
| Competing Interests: | The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. |
| References: | J Infect Dis. 2017 Aug 15;216(4):477-488. (PMID: 28931237) Int J Mol Sci. 2024 Nov 02;25(21):. (PMID: 39519352) PLoS Pathog. 2022 Jun 3;18(6):e1010095. (PMID: 35658060) J Neurosci. 2016 Feb 17;36(7):2119-30. (PMID: 26888924) PLoS Pathog. 2023 Oct 23;19(10):e1011731. (PMID: 37871034) Nat Commun. 2019 Sep 5;10(1):3994. (PMID: 31488832) PLoS Pathog. 2018 Nov 19;14(11):e1007437. (PMID: 30452468) Cell Rep. 2020 May 19;31(7):107634. (PMID: 32433977) Nucleic Acids Res. 2019 May 7;47(8):4292-4307. (PMID: 30820540) Exp Ther Med. 2020 Apr;19(4):3060-3068. (PMID: 32256793) RNA Biol. 2021 Nov 12;18(sup2):604-611. (PMID: 34747322) Cytokine. 2024 Sep;181:156693. (PMID: 38986252) Genome Res. 2015 Dec;25(12):1801-11. (PMID: 26392366) Antibiotics (Basel). 2021 Dec 16;10(12):. (PMID: 34943756) Nucleic Acids Res. 2015 Apr 30;43(8):3922-37. (PMID: 25824946) Cell Death Dis. 2020 Dec 9;11(12):1043. (PMID: 33293505) Biochem Biophys Res Commun. 2016 May 13;473(4):1229-1234. (PMID: 27079235) Epigenetics. 2019 Jun;14(6):589-601. (PMID: 31010371) Autophagy. 2022 Feb;18(2):391-408. (PMID: 34074211) J Biol Chem. 2015 Mar 13;290(11):7314-22. (PMID: 25645924) Sci Rep. 2022 Mar 17;12(1):4645. (PMID: 35301360) Microb Cell. 2016 Jan 18;3(2):92-94. (PMID: 28357339) PLoS Pathog. 2025 May 30;21(5):e1013190. (PMID: 40445981) Biochimie. 2024 Jun;221:110-124. (PMID: 38311199) Sci Rep. 2016 Feb 23;6:21624. (PMID: 26902658) PLoS Pathog. 2025 May 22;21(5):e1013207. (PMID: 40402977) Genet Test Mol Biomarkers. 2015 Dec;19(12):650-6. (PMID: 26505221) Front Cell Infect Microbiol. 2021 Jul 26;11:676456. (PMID: 34381738) J Cell Mol Med. 2025 May;29(10):e70567. (PMID: 40387517) Infect Immun. 2022 May 19;90(5):e0052221. (PMID: 35311579) Nucleic Acids Res. 2020 Nov 18;48(20):11468-11485. (PMID: 33119758) mSphere. 2021 Feb 24;6(1):. (PMID: 33627504) Sci Immunol. 2017 Mar;2(9):. (PMID: 28707004) J Microbiol Biotechnol. 2019 Jun 28;29(6):989-998. (PMID: 31154748) Int J Mol Sci. 2022 Mar 09;23(6):. (PMID: 35328388) ACS Omega. 2022 Sep 27;7(40):35901-35910. (PMID: 36249403) Biomed Res Int. 2016;2016:4323281. (PMID: 27366746) Int J Mol Sci. 2020 Apr 30;21(9):. (PMID: 32365959) NAR Mol Med. 2024 Nov 15;1(4):ugae020. (PMID: 41257247) Respir Res. 2025 Mar 05;26(1):86. (PMID: 40045290) Int J Mol Sci. 2022 Feb 26;23(5):. (PMID: 35269727) Front Pharmacol. 2026 Feb 09;17:1762214. (PMID: 41737548) BMC Infect Dis. 2016 Nov 29;16(1):722. (PMID: 27899068) Proc Natl Acad Sci U S A. 2022 Mar 29;119(13):e2109431119. (PMID: 35333652) Pathog Dis. 2023 Jan 17;81:. (PMID: 36509392) Cell. 2015 Jan 15;160(1-2):62-73. (PMID: 25594175) Proc Natl Acad Sci U S A. 2018 Jun 19;115(25):6464-6469. (PMID: 29871950) Int J Mol Sci. 2025 Nov 09;26(22):. (PMID: 41303360) Front Immunol. 2017 Aug 17;8:981. (PMID: 28861085) Mol Microbiol. 2018 Dec;110(5):811-830. (PMID: 30207611) mSystems. 2024 Sep 17;9(9):e0062824. (PMID: 39162406) PLoS One. 2017 Apr 17;12(4):e0175844. (PMID: 28414762) Front Immunol. 2017 May 24;8:602. (PMID: 28596772) FEBS J. 2016 Jan;283(2):265-81. (PMID: 26476134) mBio. 2019 Mar 26;10(2):. (PMID: 30914513) Front Cell Infect Microbiol. 2021 Mar 12;11:622487. (PMID: 33777836) Front Immunol. 2018 Feb 01;9:85. (PMID: 29449840) PLoS Pathog. 2017 Feb 13;13(2):e1006227. (PMID: 28192515) Gut Microbes. 2022 Jan-Dec;14(1):2029997. (PMID: 35343370) Immunol Rev. 2014 Nov;262(1):179-92. (PMID: 25319335) Antibiotics (Basel). 2021 Oct 29;10(11):. (PMID: 34827261) J Glob Antimicrob Resist. 2020 Dec;23:232-242. (PMID: 33045438) Sci Rep. 2021 Sep 30;11(1):19418. (PMID: 34593857) Commun Biol. 2025 Oct 6;8(1):1425. (PMID: 41053365) Sci Rep. 2018 Jan 9;8(1):160. (PMID: 29317751) iScience. 2022 Jul 20;25(8):104799. (PMID: 35982796) Elife. 2020 Oct 27;9:. (PMID: 33107429) Clin Transl Med. 2023 Aug;13(8):e1363. (PMID: 37605307) J Neuroinflammation. 2017 Feb 7;14(1):31. (PMID: 28173836) EMBO J. 2018 Jan 17;37(2):183-200. (PMID: 29170282) Tuberculosis (Edinb). 2021 Mar;127:102062. (PMID: 33639591) Ann Med. 2024 Dec;56(1):2416604. (PMID: 39435612) Int J Mol Sci. 2023 Apr 27;24(9):. (PMID: 37175635) Infect Immun. 2016 Aug 19;84(9):2505-23. (PMID: 27324481) Front Immunol. 2020 Jul 23;11:1609. (PMID: 32793237) Front Immunol. 2020 Feb 03;11:36. (PMID: 32117228) J Glob Antimicrob Resist. 2022 Dec;31:345-352. (PMID: 36347496) ACS Chem Biol. 2017 Apr 21;12(4):958-968. (PMID: 28169523) Microb Pathog. 2021 Apr;153:104778. (PMID: 33548483) Front Mol Biosci. 2022 Jun 24;9:906387. (PMID: 35813825) Elife. 2020 Jul 22;9:. (PMID: 32697192) Biochem Biophys Res Commun. 2017 Nov 25;493(3):1204-1209. (PMID: 28935371) |
| Contributed Indexing: | Keywords: acetylation; epigenetics; histone modification; methylation; non-coding RNA; tuberculosis |
| Substance Nomenclature: | 0 (Histones) |
| Entry Date(s): | Date Created: 20260916 Date Completed: 20260916 Latest Revision: 20260917 |
| Update Code: | 20260917 |
| PubMed Central ID: | PMC13576054 |
| DOI: | 10.3389/fimmu.2026.1943755 |
| PMID: | 42746448 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2026.1943755 |